| Issue |
BIO Web Conf.
Volume 59, 2023
2023 5th International Conference on Biotechnology and Biomedicine (ICBB 2023)
|
|
|---|---|---|
| Article Number | 02003 | |
| Number of page(s) | 7 | |
| Section | Precision Medicine and Drug Development and Preparation | |
| DOI | https://doi.org/10.1051/bioconf/20235902003 | |
| Published online | 08 May 2023 | |
Application of CRISPR-Cas System in the Treatment of Human Viral Disease
Xiamen No.1 High School of Fujian, Xiamen, 361001, China
* Corresponding author’s e-mail: 451627649@qq.com
CRISPR-Cas systems, consisting of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas), are the latest generation of gene editing technology and have been widely used in molecular biology research. CRISPR-Cas systems also have unlimited potential in the field of medicine, especially in the treatment of human viral diseases, such as blocking virus invasion, interfering with virus replication, and eliminating viral genome and sequelae of virus infection. In this article, the latest research progress of CRISPR-Cas9 system and other CRISPR systems in treatments of several viral diseases are reviewed. In addition, the advantages and potential problems of CRISPR systems as treatment options are analyzed to provide ideas for subsequent related research.
© The Authors, published by EDP Sciences, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.